Terms: = Prostate cancer AND CgA
195 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
3. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV
Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119
[TBL] [Abstract] [Full Text] [Related]
4. Robot assisted radical prostatectomy in fit older patients compared to a standard population: Clinical characteristics, surgical, oncological and functional outcomes.
Blezien O; Bentellis I; Tibi B; Shaikh A; Rambaud C; Boulahssass R; De Cobelli O; Chevallier D; Ahallal Y; Durand M
Prog Urol; 2023 Apr; 33(5):272-278. PubMed ID: 36764858
[TBL] [Abstract] [Full Text] [Related]
5. Chromogranin A: a useful biomarker in castration-resistant prostate cancer.
Ploussard G; Rozet F; Roubaud G; Stanbury T; Sargos P; Roupret M
World J Urol; 2023 Feb; 41(2):361-369. PubMed ID: 36527470
[TBL] [Abstract] [Full Text] [Related]
6. Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
Lombardo R; Rovesti L; Cicione A; Gravina C; Franco A; Stira J; Simone G; D'Annunzio S; Nacchia A; Papalia R; Mastroianni R; Collura D; Brassetti A; Vecchione A; Muto G; Gallucci M; Tubaro A; De Nunzio C
Prostate; 2022 Oct; 82(14):1400-1405. PubMed ID: 35923120
[TBL] [Abstract] [Full Text] [Related]
7. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
[TBL] [Abstract] [Full Text] [Related]
8. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis.
Kannan A; Clouston D; Frydenberg M; Ilic D; Karim MN; Evans SM; Toivanen R; Risbridger GP; Taylor RA
BJU Int; 2022 Oct; 130(4):420-433. PubMed ID: 34784097
[TBL] [Abstract] [Full Text] [Related]
9. Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.
Zangl Q; Wirth J; Karl A; Stief C; Zwissler B; Von Dossow V
Oncology (Williston Park); 2021 Oct; 35(9):620-627. PubMed ID: 34669360
[TBL] [Abstract] [Full Text] [Related]
10. Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy.
Mankuzhy NP; Almahariq MF; Ye H; Amin M; Stone B; Krauss DJ
Am J Clin Pathol; 2021 May; 155(6):879-886. PubMed ID: 33283224
[TBL] [Abstract] [Full Text] [Related]
11. N‑Myc induces the tumor progression of prostate cancer by regulating FSCN1.
He G; Li M; Fang L; Xu L; Huang X; Zheng L; Yang L; Luo W; Cai Y; Ma W; Liang C; Yin Y
Oncol Rep; 2020 Nov; 44(5):2265-2274. PubMed ID: 33000273
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive geriatric assessment in older patients with cancer: an external validation of the multidimensional prognostic index in a French prospective cohort study.
Liuu E; Hu C; Valero S; Brunet T; Jamet A; Bureau ML; Pilotto A; Saulnier PJ; Paccalin M
BMC Geriatr; 2020 Aug; 20(1):295. PubMed ID: 32811435
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract] [Full Text] [Related]
14. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for prostate cancer.
Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
[TBL] [Abstract] [Full Text] [Related]
15. Frailty and diabetes status in older patients with cancer: impact on mortality in the ANCRAGE cohort.
Liuu E; Saulnier PJ; Gand E; Ragot S; Valero S; Jamet A; Hadjadj S; Paccalin M
Aging Clin Exp Res; 2020 Sep; 32(9):1809-1819. PubMed ID: 31898171
[TBL] [Abstract] [Full Text] [Related]
16. Response Prediction of
Rathke H; Holland-Letz T; Mier W; Flechsig P; Mavriopoulou E; Röhrich M; Kopka K; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2020 May; 61(5):689-695. PubMed ID: 31653712
[TBL] [Abstract] [Full Text] [Related]
17. Low-serum testosterone and high-chromogranin A rare case associated with high-grade prostate cancer and higher pathological stages of the disease.
Izzo L; Cardi A; Pugliese F; Izzo S; Izzo P; Valabrega S; Messineo D; Pieretti G
Ann Ital Chir; 2019; 90():451-456. PubMed ID: 31203267
[TBL] [Abstract] [Full Text] [Related]
18. Non-functional paraganglioma of urinary bladder managed by transurethral resection.
Zhang B; Fu Z; Liu L; Qiao B; Liu C
Int Braz J Urol; 2019; 45(5):910-915. PubMed ID: 31038858
[TBL] [Abstract] [Full Text] [Related]
19. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in prostate cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract] [Full Text] [Related]
20. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant prostate cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract] [Full Text] [Related]
[Next]
